Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.mehy.2007.01.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retinal Protection of New Nutraceutical Formulation.
Pharmaceutics
January 2025
Innovation and Medical Science, SIFI S.p.A., 95025 Aci Sant'Antonio, Italy.
Retinal ganglion cell (RGC) protection represents an unmet need in glaucoma. This study assessed the neuroprotective, antioxidant, and anti-inflammatory effect of a new nutraceutical formulation named Epicolin, based on citicoline, homotaurine, epigallocatechin-3-gallate, forskolin, and vitamins, through in vitro and in vivo studies. The neuroprotective effect of Epicolin or its single components, and Epicolin compared to an untreated control and two marketed formulations [Formulation G (FG) and N (FN)], was evaluated in neuroblastoma cells (SH-SY5Y) challenged with staurosporine.
View Article and Find Full Text PDFAn update on ocular effects of anti-diabetic medications.
Surv Ophthalmol
January 2025
University of Pittsburgh, School of Medicine, PA, USA. Electronic address:
The global increase in the prevalence of type 2 diabetes has led to the development and implementation of new classes of anti-diabetic medications, introducing advanced therapeutic options for the management of the disease. These new medications, though primarily designed to regulate blood glucose levels, also have applications in weight management, potentially transforming the current approaches to diabetes treatment. Newer medications, however, have ophthalmic side effects with controversies in trials and real-life data.
View Article and Find Full Text PDFEnhancing Ophthalmic Care: The Transformative Potential of Digital Twins in Healthcare.
Cureus
December 2024
Department of Ophthalmology, Broward Health, Fort Lauderdale, USA.
This literature review explores the emerging role of digital twin (DT) technology in ophthalmology, emphasizing its potential to revolutionize personalized medicine. DTs integrate diverse data sources, including genetic, environmental, and real-time patient data, to create dynamic, predictive models that enhance risk assessment, surgical planning, and postoperative care. The review highlights vital case studies demonstrating the application of DTs in improving the early detection and management of diseases such as glaucoma and age-related macular degeneration.
View Article and Find Full Text PDFTravoprost Intracameral Implant in Eyes with Glaucoma or Ocular Hypertension: Early Short-Term Real-World Outcomes.
Clin Ophthalmol
January 2025
Harvard Eye Associates, Laguna Hills, CA, USA.
Purpose: To assess real-world efficacy and safety of standalone travoprost intracameral implant (iDose TR) implantation by a US glaucoma surgeon in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Methods: This non-randomized, retrospective, unmasked, consecutive case series included all cases of standalone iDose TR implantation from a single US glaucoma surgeon since the product's approval by the US Food and Drug Administration (FDA) in December 2023. Patients were pseudophakic, had OAG or OHT, and had undergone prior SLT and/or bimatoprost intracameral implant injection (Durysta).
Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication.
Med Gas Res
June 2025
Glaucoma Service, Wills Eye Hospital, Philadelphia, PA, USA.
Glaucoma is a chronic optic neuropathy that causes characteristic visual field defects and is considered one of the leading causes of irreversible vision loss worldwide. Lowering intraocular pressure is the only proven treatment for glaucoma. Medical therapy is usually the first-line treatment for open-angle glaucoma and ocular hypertension.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!